Associations - EGFR T790M

EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials Thorac Cancer - 3 weeks (New B)	afatinib Sensitive: B - Late Trials Thorac Cancer - 3 weeks - (New C3)
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval	lazertinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: A1 - Approval	aumolertinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials	erlotinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: B - Late Trials	erlotinib + ramucirumab Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: B - Late Trials	bevacizumab Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label	osimertinib Resistant: C1 - Off-label
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	osimertinib Sensitive: C1 - Off-label	osimertinib Sensitive: C1 - Off-label
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	rociletinib Sensitive: C2 – Inclusion Criteria	rociletinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	ASP8273 Sensitive: C2 – Inclusion Criteria	ASP8273 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	ASK120067 Sensitive: C2 – Inclusion Criteria	ASK120067 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	olmutinib Sensitive: C2 – Inclusion Criteria	olmutinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: C2 – Inclusion Criteria	lazertinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	anlotinib Sensitive: C2 – Inclusion Criteria	anlotinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	furmonertinib Sensitive: C2 – Inclusion Criteria	furmonertinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	abivertinib Sensitive: C2 – Inclusion Criteria	abivertinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	D-0316 Sensitive: C2 – Inclusion Criteria	D-0316 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	SH-1028 Sensitive: C2 – Inclusion Criteria	SH-1028 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C3 – Early Trials	bevacizumab + osimertinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	APL-103 Sensitive: C3 – Early Trials	APL-103 Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	WZ4002 Sensitive: C3 – Early Trials	WZ4002 Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: C3 – Early Trials	erlotinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	imatinib Sensitive: C3 – Early Trials	imatinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib + ruxolitinib Sensitive: C3 – Early Trials	afatinib + ruxolitinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	cetuximab + brigatinib Sensitive: C3 – Early Trials	cetuximab + brigatinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib + ramucirumab Sensitive: C3 – Early Trials	osimertinib + ramucirumab Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Resistant: C3 – Early Trials	bevacizumab + erlotinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + gefitinib Resistant: C3 – Early Trials	bevacizumab + gefitinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + APG-1252 Sensitive: C3 – Early Trials	osimertinib + APG-1252 Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials	brigatinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	BPI-7711 Sensitive: C3 – Early Trials	BPI-7711 Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ABCP Sensitive: C3 – Early Trials	ABCP Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Gallbladder Cancer Gallbladder Cancer	EGFR T790M EGFR T790M	Gallbladder Cancer Gallbladder Cancer	erlotinib Sensitive: C4 – Case Studies	erlotinib Sensitive: C4 – Case Studies
EGFR T790M EGFR T790M	Pancreatic Cancer Pancreatic Cancer	EGFR T790M EGFR T790M	Pancreatic Cancer Pancreatic Cancer	erlotinib Resistant: C4 – Case Studies	erlotinib Resistant: C4 – Case Studies
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	APG-1252 Sensitive: D – Preclinical	APG-1252 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + DC101 Sensitive: D – Preclinical	osimertinib + DC101 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: D – Preclinical	amivantamab-vmjw Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib + PF-03084014 Sensitive: D – Preclinical	gefitinib + PF-03084014 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	MTI-31 Sensitive: D – Preclinical	MTI-31 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	neratinib + PF-05212384 Sensitive: D – Preclinical	neratinib + PF-05212384 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	neratinib Sensitive: D – Preclinical	neratinib Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	BMS-722782 Sensitive: D – Preclinical	BMS-722782 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	Compound 6a Sensitive: D – Preclinical	Compound 6a Sensitive: D – Preclinical